Product Name: Nesiritide
Form: Acetate salt
CAS No: 124584-08-3
Molar Mass: 3464.04
Chemical Formula: C143H244N50O42S4
Synonyms: BNP 32, Human brain natriuretic factor-32, Natriuretic peptide type-B
Storage: Store at -20℃
Sequence: SPKMVQGSGC FGRKMDRISS SSGLGCKVLR RH
Target: NPRs
Application:
Nesiritide (CAS: 124584-08-3) is a recombinant form of human B-type natriuretic peptide (BNP), a hormone produced by the heart ventricles in response to increased cardiac wall stress. It functions as a vasodilator and diuretic, primarily targeting natriuretic peptide receptors, particularly the type A receptor (NPR-A), located in vascular smooth muscle cells and the kidneys. Nesiritide promotes vasodilation, natriuresis, and diuresis, thereby reducing cardiac preload and afterload, as well as relieving fluid overload in conditions such as acute decompensated heart failure (ADHF). In pharmaceutical chemistry, nesiritide's structure and mechanism of action make it a valuable therapeutic option for managing acute heart failure, providing rapid symptom relief and improving hemodynamic parameters. Its application underscores its significance in addressing the complex pathophysiology of heart failure and improving patient outcomes. Additionally, ongoing research explores nesiritide's potential in other cardiovascular conditions and its role in combination therapies, highlighting its versatility in cardiovascular medicine.
Current Research:
Nesiritide is a recombinant human B-type natriuretic peptide (BNP) used primarily in the treatment of acute decompensated heart failure (ADHF), especially in patients who present with severe symptoms of fluid overload and shortness of breath. It acts as a vasodilator, promoting the relaxation of blood vessels and reducing the workload on the heart. Nesiritide is administered intravenously in hospital settings and is typically used for short-term management to stabilize patients before further therapeutic interventions or to improve symptoms while awaiting other long-term treatments for heart failure.
Mechanism of Action
Nesiritide mimics the natural effects of BNP, a peptide produced by the heart in response to increased wall stress due to heart failure. BNP binds to natriuretic peptide receptors, which activate several pathways to decrease blood volume and reduce cardiac workload. The primary actions of nesiritide include vasodilation (relaxation of blood vessels), natriuresis (increased sodium excretion by the kidneys), and diuresis (increased urine production). This leads to reduced preload (the volume of blood returning to the heart) and afterload (the resistance the heart must overcome to eject blood), easing the burden on the heart and improving symptoms of fluid overload. Additionally, nesiritide has a mild effect on increasing renal blood flow and reducing systemic vascular resistance.
Indications and Uses
Nesiritide is indicated for the intravenous treatment of acute decompensated heart failure (ADHF) with symptoms of fluid overload. It is particularly useful in patients who exhibit significant dyspnea (shortness of breath) and edema despite conventional therapies such as diuretics or afterload reducers. Nesiritide is administered in a hospital setting as part of the acute management of heart failure exacerbations, with a focus on symptom relief. Its use is typically short-term and often follows the stabilization of patients to improve clinical outcomes and support transition to other long-term heart failure management strategies, such as ACE inhibitors, beta-blockers, or diuretics.
Efficacy and Clinical Benefits
Clinical studies have demonstrated that nesiritide effectively reduces symptoms of acute heart failure, particularly dyspnea and fluid overload. Nesiritide administration leads to rapid relief of these symptoms by promoting vasodilation and improving cardiac output. Studies have shown that nesiritide reduces pulmonary capillary wedge pressure (PCWP), a measure of cardiac filling pressures that is elevated in heart failure, as well as improving exercise tolerance and reducing the need for additional intravenous diuretics. Although nesiritide provides symptomatic relief and stabilizes patients with ADHF, its impact on long-term outcomes such as mortality and readmission rates remains uncertain and is an area of ongoing investigation.
Safety and Tolerability
Nesiritide is generally well tolerated, but it can cause some side effects. The most common adverse effects are hypotension (low blood pressure), especially during the initial stages of administration, as a result of the vasodilatory effects of the drug. Other side effects may include dizziness, headache, nausea, and potential renal dysfunction due to its natriuretic and diuretic actions. Although nesiritide does not have the significant adverse effects associated with other vasodilators, such as nitrates, its use requires close monitoring of blood pressure and renal function, particularly in patients with preexisting renal impairment or hypotension. In rare cases, prolonged administration can lead to worsened renal function, requiring cessation of treatment.
Advantages and Limitations
The main advantage of nesiritide is its ability to provide rapid symptomatic relief in patients with acute decompensated heart failure, particularly in those with severe fluid overload. Unlike other therapies such as diuretics, which only address fluid retention, nesiritide works by reducing both preload and afterload, improving both the hemodynamic and symptomatic aspects of heart failure. However, its clinical use is limited by the lack of robust evidence showing long-term survival benefits, making it a supportive therapy rather than a definitive treatment for heart failure. Furthermore, the cost of nesiritide can be a limitation, as it is typically more expensive compared to other therapies like intravenous loop diuretics.
Future Directions
Ongoing research into nesiritide is focused on evaluating its role in the management of heart failure in different patient populations, such as those with preserved ejection fraction (heart failure with preserved ejection fraction, or HFpEF). Additionally, studies are exploring the potential of combining nesiritide with other novel therapies, such as neprilysin inhibitors or angiotensin receptor-neprilysin inhibitors (ARNIs), to enhance its effects and improve long-term outcomes. There is also interest in exploring the safety and efficacy of nesiritide in outpatient settings or as part of broader heart failure management strategies that aim to prevent hospitalizations or progression of the disease.
Reference:
Get a Quote
LinkPeptide
